We sell in-depth short-selling reports for any company ₿ 0.10 BTC.
Contact us today.
Short Interest Update USNVAX

NVAX Short Interest Climbs to 29% of Float

Novavax Inc. (NVAX) has seen a significant increase in open short positions, with short interest rising to 29% of the available float according to the latest reporting period.

Powered by NegativePublicRelations.com
By The Forensic Ledger Desk October 8, 20262 min read
Company
Novavax Inc.
Short % Float
29%
Days to Cover
14.03

Rising Bearish Sentiment in NVAX

Novavax Inc. (NASDAQ:NVAX) is currently facing heightened short-selling pressure. According to the most recent official FINRA data, short interest in the company has climbed to 47.49 million shares, representing approximately 29% of the company's publicly available float. This marks a notable increase from the previous reporting period, where short interest stood at 45.66 million shares.

Liquidity and Days to Cover

The surge in short interest, combined with current trading volumes, has pushed the 'days to cover' metric to 14.03. This indicates that, based on an average daily volume of 3.38 million shares, it would take over two weeks for short sellers to fully exit their positions without causing significant upward price volatility. Investors should monitor this closely, as high 'days to cover' ratios often serve as a precursor to potential short squeeze volatility if the stock price begins to trend upward.

Key Takeaways

  • Short interest in NVAX has increased to 47.49 million shares.
  • The short interest as a percentage of float now stands at 29%.
  • The 'days to cover' ratio is currently 14.03, suggesting a high level of difficulty for shorts to exit quickly.

The Bottom Line

With nearly 30% of its float shorted and a high days-to-cover ratio, NVAX remains a high-conviction target for bearish traders, but also a prime candidate for a potential short squeeze should market sentiment shift.

Source

Signal data sourced from Benzinga. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.

#Short Interest#NVAX#Biotech

Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.

Commission a Report · The Forensic Ledger Desk

Forensic Research & Investigations

We conduct deep investigative research into publicly traded companies — deploying forensic accountants, field investigators, and industry experts to uncover business fraud (overstated revenues), accounting fraud (inflated profits), or severe fundamental business flaws.

Commission us to compose a short-seller research report on a company you target. Every dossier is built to evidentiary standards — sourced, falsifiable, and ready to move markets. Costs: ₿ 0.10 BTC

Commission a Report
Business Fraud

Overstated revenues, fake channels, pulled-forward demand.

Accounting Fraud

Inflated profits, aggressive recognition, hidden liabilities.

Fundamental Flaws

Structural business defects the market has mispriced.

The Negative PR Blog

The internet's leading source on negative PR campaigns, smear campaigns, bad press, and reputation warfare — real, recent events documented and dissected by our reporters, with expert analysis of how we'd respond.

Read the Blog
Contact Us on Telegram